

Tuna Mutis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5056431/publications.pdf>

Version: 2024-02-01

96
papers

4,001
citations

147801

31
h-index

123424

61
g-index

96
all docs

96
docs citations

96
times ranked

4572
citing authors

#	ARTICLE	IF	CITATIONS
1	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	3.5	63
2	Tumour Escape from CAR-T Cells. , 2022, , 15-22.		4
3	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <i>Leukemia</i> , 2021, 35, 573-584.	7.2	67
4	Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. <i>Blood Cancer Journal</i> , 2021, 11, 38.	6.2	36
5	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. <i>Clinical Cancer Research</i> , 2021, 27, 3793-3803.	7.0	27
6	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2196-2215.	5.2	56
7	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. <i>HemaSphere</i> , 2021, 5, e561.	2.7	11
8	Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2165-2172.	5.2	9
9	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 2452.	3.7	11
10	Efficacy and safety of daratumumab combined with all- <i>trans</i> retinoic acid in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5128-5139.	5.2	22
11	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4593.	2.4	11
12	High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial. <i>Blood</i> , 2021, 138, 1414-1414.	1.4	0
13	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. <i>Science Translational Medicine</i> , 2021, 13, eabh1962.	12.4	49
14	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2020, 105, e80-e83.	3.5	12
15	Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. <i>Haematologica</i> , 2020, 105, e302-e306.	3.5	53
16	Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 1362.	2.8	45
17	Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3052.	3.7	13
18	Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2089-2104.	4.1	3

#	ARTICLE	IF	CITATIONS
19	Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e463.	2.7	5
20	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. <i>Cancers</i> , 2020, 12, 3713.	3.7	23
21	Targeted Therapy With Immunoconjugates for Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1155.	4.8	38
22	Preclinical Activity of JNJ-7957, a Novel BCMA α -CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. <i>Clinical Cancer Research</i> , 2020, 26, 2203-2215.	7.0	53
23	Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance. <i>Cancers</i> , 2020, 12, 988.	3.7	46
24	Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma. <i>Blood</i> , 2020, 136, 8-9.	1.4	6
25	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. <i>Oncotarget</i> , 2020, 11, 4076-4081.	1.8	23
26	Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. <i>Journal of Controlled Release</i> , 2019, 296, 232-240.	9.9	27
27	Immunotherapy in myeloma: how far have we come?. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882266.	2.5	47
28	T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells. <i>Cancer Immunology Research</i> , 2019, 7, 797-804.	3.4	15
29	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor α -engineered T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4014-4025.	7.0	110
30	CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, e100-e103.	3.5	90
31	High α -Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 279-289.	1.5	117
32	Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies. <i>Blood</i> , 2019, 134, 3106-3106.	1.4	14
33	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. <i>Blood</i> , 2019, 134, 137-137.	1.4	10
34	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. <i>Blood</i> , 2019, 134, 3227-3227.	1.4	1
35	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 197-206.	3.0	30
36	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. <i>Haematologica</i> , 2018, 103, e368-e371.	3.5	43

#	ARTICLE	IF	CITATIONS
37	Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS ONE, 2018, 13, e0197349.	2.5	60
38	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget, 2018, 9, 34009-34021.	1.8	17
39	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 2017, 25, 1946-1958.	8.2	197
40	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research, 2017, 23, 7498-7511.	7.0	134
41	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 2016, 101, 616-625.	3.5	136
42	Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. European Journal of Haematology, 2016, 97, 479-488.	2.2	15
43	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 2016, 128, 2297-2306.	1.4	49
44	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood, 2016, 128, 384-394.	1.4	697
45	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, 2016, 128, 959-970.	1.4	286
46	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews, 2016, 270, 95-112.	6.0	280
47	Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica, 2016, 101, e339-e342.	3.5	34
48	Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization. Blood, 2016, 128, 2170-2170.	1.4	9
49	High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action. Blood, 2016, 128, 4521-4521.	1.4	8
50	HY antibodies as biomarkers for chronic GVHD. Blood, 2015, 125, 3046-3047.	1.4	2
51	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica, 2015, 100, 263-268.	3.5	96
52	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clinical Cancer Research, 2015, 21, 2802-2810.	7.0	136
53	Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma. Blood, 2015, 126, 3037-3037.	1.4	9
54	Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations. Blood, 2015, 126, 4174-4174.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2 Restricted T Cell Epitopes. <i>Journal of Immunology</i> , 2014, 193, 4803-4813.	0.8	40
56	Identification of minor histocompatibility antigens based on the 1000 Genomes Project. <i>Haematologica</i> , 2014, 99, 1854-1859.	3.5	43
57	Detection of choroid- and retina-antigen reactive CD8+ and CD4+ T lymphocytes in the vitreous fluid of patients with birdshot chorioretinopathy. <i>Human Immunology</i> , 2014, 75, 570-577.	2.4	41
58	Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All-Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab. <i>Blood</i> , 2014, 124, 2096-2096.	1.4	3
59	CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma. <i>Blood</i> , 2014, 124, 4759-4759.	1.4	8
60	Toll-Like Receptor (TLR)-1/2 Triggering of Multiple Myeloma Cells Modulates Their Adhesion to Bone Marrow Stromal Cells and Enhances Bortezomib-Induced Apoptosis. <i>PLoS ONE</i> , 2014, 9, e96608.	2.5	15
61	Identification of Minor Histocompatibility Antigens Based on the 1000 Genomes Project for Application in Therapeutic Dendritic Cell Vaccination. <i>Blood</i> , 2014, 124, 2418-2418.	1.4	0
62	Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 5591-5601.	7.0	48
63	CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients. <i>Blood</i> , 2013, 122, 277-277.	1.4	4
64	Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study). <i>Blood</i> , 2013, 122, 287-287.	1.4	2
65	Preclinical Evaluation Of Engineered T Cells In Multiple Myeloma: Uncovering a Mechanism Of Immune Escape. <i>Blood</i> , 2013, 122, 4205-4205.	1.4	0
66	Improved Vaccine Design For Adoptive Immunotherapy In Hematological Malignancies Through Chemically Modified Minor Histocompatibility Antigen Epitopes. <i>Blood</i> , 2013, 122, 5435-5435.	1.4	0
67	The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model. <i>Blood</i> , 2013, 122, 3250-3250.	1.4	0
68	Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma. <i>Blood</i> , 2013, 122, 2005-2005.	1.4	0
69	Interleukin-17 production and T helper 17 cells in peripheral blood mononuclear cells in response to ocular lysate in patients with birdshot chorioretinopathy. <i>Molecular Vision</i> , 2013, 19, 2606-14.	1.1	21
70	Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. <i>Blood</i> , 2012, 120, e9-e16.	1.4	104
71	Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model. <i>Blood</i> , 2012, 120, 1834-1834.	1.4	1
72	Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients. <i>Blood</i> , 2012, 120, 4988-4988.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model. <i>Blood</i> , 2012, 120, 940-940.	1.4	3
74	Epigenetic Regulation of Cancer-Testis Antigen Expression in Multiple Myeloma and Correlation with High-Risk Cytogenetics.. <i>Blood</i> , 2012, 120, 2923-2923.	1.4	0
75	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. <i>Haematologica</i> , 2011, 96, 284-290.	3.5	212
76	Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients. <i>Blood</i> , 2011, 118, 1865-1865.	1.4	23
77	Identification of New Hematopoietic Minor Histocompatibility Antigen UTA2-1; Ready for Application in Antitumor Immunotherapy. <i>Blood</i> , 2011, 118, 2979-2979.	1.4	0
78	Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,. <i>Blood</i> , 2011, 118, 3412-3412.	1.4	0
79	The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro. <i>Blood</i> , 2011, 118, 5106-5106.	1.4	1
80	Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),. <i>Blood</i> , 2011, 118, 4039-4039.	1.4	0
81	Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. <i>Blood</i> , 2011, 118, 1838-1838.	1.4	3
82	In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma. <i>Blood</i> , 2010, 116, 3058-3058.	1.4	4
83	Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab. <i>Blood</i> , 2010, 116, 3059-3059.	1.4	1
84	Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma: Results of the HOVON 76 Study. <i>Blood</i> , 2010, 116, 3502-3502.	1.4	2
85	Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib. <i>Blood</i> , 2010, 116, 3030-3030.	1.4	0
86	A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing. <i>Blood</i> , 2010, 116, 981-981.	1.4	0
87	Bone Marrow Neutralizes Human Regulatory T-Cells to Permit Graft-Versus-Tumor Immunity In Humanized Mice. <i>Blood</i> , 2010, 116, 1017-1017.	1.4	2
88	Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 2875-2875.	1.4	0
89	Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.. <i>Blood</i> , 2009, 114, 1333-1333.	1.4	1
90	Rebuilding Human Leukocyte Antigen Class IIâ€™-Restricted Minor Histocompatibility Antigen Specificity in Recall Antigen-Specific T Cells by Adoptive T Cell Receptor Transfer: Implications for Adoptive Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 4009-4015.	7.0	22

#	ARTICLE	IF	CITATIONS
91	Lenalidomide Is Highly Effective in Patients with Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplantation and Increases the Frequency of CD4+FOXP3+ T Cells.. Blood, 2007, 110, 2722-2722.	1.4	1
92	A Single Nucleotide Polymorphism in CD19 Defines a Novel Target for Immunotherapy of B Cell Malignancies with CD4+ Cytotoxic T Cells.. Blood, 2007, 110, 1798-1798.	1.4	0
93	A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution. British Journal of Haematology, 2005, 128, 73-81.	2.5	19
94	Generation of CD4+ Regulatory T Cells by Retroviral Transduction of CD4+CD25 ^{hi} T Cells Either with the Full-Length or with a Common Exon-2 Negative Variant of Human Foxp3.. Blood, 2005, 106, 3315-3315.	1.4	1
95	Human CD4+ CD25+ Regulatory T Cells Effectively Control Xenogeneic-GvHD Induced by Autologous T Cells in Rag2 ^{hi} /Î³c ^{hi} Immune-Deficient Mice.. Blood, 2004, 104, 301-301.	1.4	0
96	Targeting Alloreactive Donor T-Cells to Hematopoietic System-Restricted Minor Histocompatibility Antigens to Dissect Graft-versus-Leukemia Effects from Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. International Journal of Hematology, 2003, 78, 208-212.	1.6	20